SCHEMBL20135067

SCHEMBL20135067

CC[C@]1(c2ccc(C(=O)N3CCC(c4cc(-c5ccc(C)cc5)[nH]n4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.39
ADAMTS5 Q9UNA0 4/20 0.38
MMP2 P08253 2/20 0.38
ABL1 P00519 2/20 0.38
BCR P11274 2/20 0.38
MMP13 P45452 1/20 0.38
UBE2M P61081 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37
MMP9 P14780 1/20 0.37
CRBN Q96SW2 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ADAMTS7 Q9UKP4 1/20 0.35
GAA P10253 1/20 0.35
MAPK7 Q13164 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135064 0.89 ADAM17 (0.39) ADAM17ADAMTS5MMP2ABL1BCR
SCHEMBL20135068 0.89 ADAM17 (0.39) ADAM17ADAMTS5MMP2ABL1BCR
SCHEMBL20791692 0.89 ABL1 (0.41) MMP2ABL1BCRUBE2MDCUN1D1
SCHEMBL20135329 0.81 ADAMTS5 (0.41) ADAM17ADAMTS5MEN1KMT2ACYP2C9
SCHEMBL20135328 0.81 ADAMTS5 (0.41) ADAM17ADAMTS5MEN1KMT2ACYP2C9
SCHEMBL20135479 0.80 ADAM17 (0.39) ADAM17ADAMTS5MMP2MMP13UBE2M
SCHEMBL20135225 0.80 ADAMTS5 (0.38) ADAM17ADAMTS5MMP2MMP13UBE2M
SCHEMBL20135476 0.80 ADAM17 (0.39) ADAM17ADAMTS5MMP2MMP13UBE2M
SCHEMBL20135224 0.80 ADAMTS5 (0.38) ADAM17ADAMTS5MMP2MMP13UBE2M
SCHEMBL20791691 0.78 UBE2M (0.40) ADAM17ADAMTS5MMP2ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAM17 36/4885ADAMTS5 23/4885MMP2 4/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAM17 39/4885ADAMTS5 25/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.